As of Wednesday close, Avadel Pharmaceuticals plc’s (NASDAQ:AVDL) stock was down -$0.17, moving down -2.13 percent to $7.81. The average number of shares traded per day over the past five days has been 1,087,840 shares. 2 times new highs have been achieved over the past 5 days, with a $0.19 gain in that time frame. In the last twenty days, the average volume was 814,455, while in the previous 50 days, it was 710,916.
Since last month, AVDL stock rose 33.50%. Shares of the company fell to $5.33 on 10/24/22, the lowest level in the past month. A 52-week high of $10.00 was reached on 10/05/22 after having rallying from a 52-week low of $1.05. Since the beginning of this year, AVDL’s stock price has dropped by -3.34% or -$0.27, and marked a new high 3 times. However, the stock has declined by -21.90% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
AVDL stock investors should be aware that Avadel Pharmaceuticals plc (AVDL) stock had its last reported insider trading activity 2 days ago on Nov 22. Ende Eric J, the Director of the company, purchased of 20,000 shares for $7.80 on Nov 22. It resulted in a $156,050 investment by the insider. Glass Geoffrey Michael added 45,000 shares at an average price of $2.14 on Jun 01. The insider now owns 45,000 shares following the transaction. On Jun 01, Director Ende Eric J bought 20,000 shares at $2.27 apiece. The transaction was valued at $45,496.
In the three months ended June 29, Avadel Pharmaceuticals plc’s quick ratio stood at 2.70, while its current ratio was 2.70, showing that the company is able to pay off its debt.
In Avadel Pharmaceuticals plc’s quarter-end financial report for June 29, it reported total debt of $109.93 million against cash and short-term investments of $45.76 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Avadel Pharmaceuticals plc to report -$0.41 quarterly earnings, the actual figure was -$1.07 per share, beating the consensus estimate by -161.00%. During the quarter, the company generated -$16.56 million in EBITDA. The liabilities of Avadel Pharmaceuticals plc were 158.2 million at the end of its most recent quarter ended June 29, and its total debt was $136.51 million.
This quick technical analysis looks at Avadel Pharmaceuticals plc’s (AVDL) price momentum. With a historical volatility rate of 147.37%, the RSI 9-day stood at 58.57% on 23 November.
With respect to its five-day moving average, the current Avadel Pharmaceuticals plc price is up by +2.49% percent or $0.19. At present, AVDL shares trade +23.77% above its 20-day simple moving average and +116.94% percent above its 100-day simple moving average. However, the stock is currently trading approximately +27.61% above its SMA50 and +29.52% above its SMA200.
Stochastic coefficient K was 76.48% and Stochastic coefficient D was 75.26%, while ATR was 0.82. Given the Stochastic reading of 70.23% for the 14-day period, the RSI (14) reading has been calculated as 58.93%. As of today, the MACD Oscillator reading stands at 0.13, while the 14-day reading stands at 0.78.
Avadel Pharmaceuticals plc downgraded its rating on Avadel Pharmaceuticals plc (NASDAQ: AVDL) to a Hold in a note to investors on August 10, 2022. The analysts firm previously had a Buy rating on the stock.Avadel Pharmaceuticals plc (AVDL) has been rated Buy by analysts. According to 0 brokerage firms, AVDL is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Avadel Pharmaceuticals plc stock as buy, with 8 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $6.50 – $19.00. Based on these forecasts, analysts predict Avadel Pharmaceuticals plc (AVDL) will achieve an average price target of $12.44.